| HER2-Positive Breast Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.98 |
| Breast Cancer |
0 |
0.99 |
| Antineoplastic Drug |
0 |
0.8 |
| Toxicology |
0 |
0.63 |
| Humanized Monoclonal Antibody |
0 |
0.51 |
| Tumor |
0 |
0.51 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.5 |
| Otolaryngology |
0 |
0.5 |
| Dentistry and Oral Health |
0 |
0.45 |
| Cancer |
0 |
0.41 |
| Food and Drug Administration (FDA) |
0 |
0.31 |
| Platelet Count |
0 |
0.17 |
| Adenocarcinoma of the Gastroesophageal Junction |
0 |
0.14 |
| Interstitial Lung Disease |
0 |
0.14 |
| Upper Respiratory Tract Infection |
0 |
0.14 |
| White Blood Cell Count |
0 |
0.14 |
| Alopecia |
0 |
0.12 |
| Diarrhea |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.12 |
| Hodgkin Lymphoma |
0 |
0.12 |
| Adenocarcinoma |
0 |
0.1 |
| Antibody Drug Conjugates |
0 |
0.1 |
| Blood |
0 |
0.1 |
| Breast |
0 |
0.1 |
| Clinical Research |
0 |
0.1 |
| Fatigue |
0 |
0.1 |
| Hemoglobin |
0 |
0.1 |
| Intravenous |
0 |
0.1 |
| Lung |
0 |
0.1 |
| Lymphocytes |
0 |
0.1 |
| Nausea |
0 |
0.1 |
| Neutrophils |
0 |
0.1 |
| Respiratory Tract |
0 |
0.1 |
| Stomatitis |
0 |
0.1 |
| Texas |
0 |
0.1 |